Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety and Tolerability of FRSW117 in Severe Hemophilia A
NCT04864743Phase 1Completed
- Sponsor
- Gensciences
- Start
- Jun 2021
- Primary completion
- Oct 2021
- Modality
- PEGylated Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of pegylated recombinant human coagulation factor VIII-Fc fusion protein in hemophilia A (2 cohorts), sponsored by Gensciences. Primary endpoints: Maximum Plasma Concentration (Cmax) for FRSW117, Half-Life (T1/2) for FRSW117 and 9 more. Started Jun 2021; status: completed.
02
Drugs
pegylated recombinant human coagulation factor VIII-Fc fusion protein
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT04864743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04864743.